Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients
2013 (English)In: Oncology Reports, ISSN 1021-335X, Vol. 29, no 4, 1467-1474 p.Article in journal (Refereed) Published
Reduced or absent Wwox expression has recently been associated with tamoxifen resistance in breast cancer and has also been proposed as a candidate predictive marker for treatment. We aimed to investigate the correlation of Wwox expression with the outcome of tamoxifen treatment by examining tissues from 912 randomized breast cancer patients. Paraffin-embedded tissues from patient tumors were arranged on tissue microarray, and Wwox protein was stained using immunohistochemistry. After microscopic examination, the results were analyzed with Cox regression, Kaplan-Meier survival curves and the log-rank test. In the group of cases having a tumor absent for Wwox expression, there was no difference in recurrence-free survival between treated and untreated patients (P=0.81). For treated cases with a tumor expressing moderate or strong Wwox protein, recurrence-free survival was improved (P=0.001 and P=0.003, respectively). The test for interaction between Wwox and treatment response demonstrated a decreased risk of recurrence for treated patients with a moderate or strong Wwox expression (HR=0.31, 95% CI 0.10-0.98 and HR=0.28, 95% CI 0.08-0.97, respectively). Our results indicate that patients with high expression of Wwox may gain more benefit from treatment with tamoxifen.
Place, publisher, year, edition, pages
Spandidos Publications , 2013. Vol. 29, no 4, 1467-1474 p.
Wwox; breast cancer; tamoxifen; randomized patients
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-96159DOI: 10.3892/or.2013.2261ISI: 000316510600028OAI: oai:DiVA.org:liu-96159DiVA: diva2:640711